Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Foundayo is the first oral GLP-1 for weight loss that has no food or water restrictions.
read more
According to the FDA, there is "reasonable evidence of a causal association" between Tavneos use and liver injury.
read more
The company is developing oral OX2R agonists, a new class of medicine that has the potential to be best in class for treating sleep-wake disorders.
read more
The deal will give Lilly access to several potentially best-in-class, novel oral therapeutics for various indications.
read more
Aimed at patients with hypercholesterolemia, the drug showed greater efficacy than three guideline-recommended oral non-statins.
read more
Key to the deal is Tern's lead candidate, TERN-701, an oral drug in phase 1/2 development for chronic myeloid leukemia.
read more
The drugmaker will build up its tablets/capsules and packaging plant in Changping, as well as expand its headquarters in Shanghai.
read more
Icotyde is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill.
read more
The drug is approved for improving walking in MS patients but there is a risk of seizures for patients with renal impairment.
read more
The hub will manufacture APIs and finished drug products to strengthen the domestic supply chain.
read more
Finerenone is already approved for chronic kidney disease associated with type 2 diabetes, but patients with non-diabetic CKD have few treatment options.
read more
This is the highest efficacy of any oral GLP-1 to date, with a comparable efficacy to injectables.
read more
The company's global footprint will be further streamlined to 10 sites.
read more
If approved, azetukalner would be the only KV7 potassium channel opener available for the treatment of epilepsy.
read more
The trial data underscore the potential of MeziKd as an oral regimen that could address a key unmet need for patients who relapse.
read more